Paul Hutson
Professor (CHS) in the University of Wisconsin–Madison School of Pharmacy; Director of the UW–Madison Transdisciplinary Center for Research in Psychoactive Substances
Data updated
Research Footprint
Paul Hutson appears in 5 tracked papers (2017–2024), most studied alongside Psilocybin, across Substance Use Disorders (SUD), Healthy Volunteers and Safety & Risk Management.
Most-cited paper: The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis (230 citations).
Frequent co-authors: Christopher Nicholas, Charles Raison and Nicholas Cozzi.
Background & Research
Paul Hutson is a pharmacist-scientist at the University of Wisconsin–Madison whose clinical research focuses on the safety and therapeutic potential of psilocybin and other psychoactive medications. He completed training in biochemistry, chemistry, pharmacy, and oncology pharmacokinetics, and has served for years on the School of Pharmacy faculty. He directs the UW–Madison Transdisciplinary Center for Research in Psychoactive Substances, which supports psychedelic and related research across campus.
Key Impact
He is a leading UW–Madison investigator in psychedelic science who helped launch the university’s first psilocybin clinical trial and continues to study psilocybin for psychiatric and substance-use indications.
Collaboration Network
5 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Paul Hutson is associated with.